HIV resistance to dolutegravir varies with co-administered agents

dc.contributor.authorBeck, Ingrid A.
dc.contributor.authorBoyce, Ceejay L.
dc.contributor.authorBishop, Marley D.
dc.contributor.authorOldroyd, Alyssa R.
dc.contributor.authorDu Toit, Louise de Villiers
dc.contributor.authorSaimen, Amashnee
dc.contributor.authorRamarope, Kholofelo Mn
dc.contributor.authorHitchcock, Sonia
dc.contributor.authorDu Plessis, Nicolette Marie
dc.contributor.authorMbogo, Loice
dc.contributor.authorChohan, Bhavna H.
dc.contributor.authorMaheria, Pooja
dc.contributor.authorOyaro, Patrick
dc.contributor.authorKnowles, Kevin
dc.contributor.authorZhang, Zhongli
dc.contributor.authorBrummel, Sean S.
dc.contributor.authorDrain, Paul K.
dc.contributor.authorSmith, Robert A.
dc.contributor.authorGottlieb, Geoffrey S.
dc.contributor.authorAbuogi, Lisa
dc.contributor.authorPatel, Rena C.
dc.contributor.authorFarquhar, Carey
dc.contributor.authorWiznia, Andrew
dc.contributor.authorRuel, Theodore D.
dc.contributor.authorRossouw, Theresa M.
dc.contributor.authorHawes, Stephen E.
dc.contributor.authorFrenkel, Lisa M.
dc.date.accessioned2026-05-28T06:29:21Z
dc.date.issued2026-04-15
dc.description.abstractWe hypothesized that HIV-dolutegravir resistance is more frequent when coadministered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200 c/mL) participants from 4 cohorts (N = 660 participants) found dolutegravir resistance in 21 (11.5%). Dolutegravir resistance was greater with dolutegravir + lamivudine + zidovudine/(1 on stavudine) (odds ratio [OR] = 19.4, 95% confidence interval [CI]: 5.1–74.3) or dolutegravir + lamivudine +abacavir (OR = 5.4, 95% CI: 1.1–25.8), compared with dolutegravir + lamivudine + tenofovir.
dc.description.departmentImmunology
dc.description.embargo2027-04-15
dc.description.librarianhj2026
dc.description.sdgSDG-03: Good health and well-being
dc.description.urihttps://academic.oup.com/cid
dc.identifier.citationBeck, I.A., Boyce, C.L., Bishop, M.D., et al. 2026, 'HIV Resistance to Dolutegravir Varies With Coadministered Agents', Clinical Infectious Diseases, Volume 82, Issue 4, Pages 592–596, https://doi.org/10.1093/cid/ciaf481.
dc.identifier.issn1058-4838 (print)
dc.identifier.issn1537-6591 (online)
dc.identifier.other10.1093/cid/ciaf481
dc.identifier.urihttp://hdl.handle.net/2263/110303
dc.language.isoen
dc.publisherOxford University Press
dc.rights© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Clinical Infectious Diseases, vol. 82, no. 4, pp. 592–596, 2026, doi : 10.1093/cid/ciaf481, is available online at : https://academic.oup.com/cid.
dc.subjectHIV resistance
dc.subjectHuman immunodeficiency virus (HIV)
dc.subjectDolutegravir
dc.subjectHIV-dolutegravir resistance
dc.subjectTenofovir
dc.subjectResistance
dc.subjectZidovudine
dc.subjectAbacavir
dc.titleHIV resistance to dolutegravir varies with co-administered agents
dc.typePostprint Article

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Immunology)
Research Articles (University of Pretoria)
Simple item page